U.S., April 22 -- ClinicalTrials.gov registry received information related to the study (NCT07543289) titled 'Pharmacogenetics and Model-Informed Optimisation of Hydroxyurea' on April 15.
Brief Summary: The wide interindividual variability in clinical response to hydroxyurea therapy in the management of sickle cell disease has limited its use. These variabilities have been linked to differences in pharmacodynamics, pharmacokinetics, and pharmacogenetics. This study, therefore, aims to enhance understanding of these factors as they relate to hydroxyurea therapy, with the overall goal of developing a precision medicine algorithm.
The study will be a prospective cohort pharmacokinetic study of 100 Nigerian patients with sickle cell disease, ...